UK maker of advanced wound care, ostomy, continence and infusion-care medical devices for chronic condition management.
UK maker of advanced wound care, ostomy, continence and infusion-care medical devices for chronic condition management.
Sells products patients reorder again and again, such as ostomy pouches and wound dressings, mostly through medical-supply distributors and reimbursed by insurers or health systems, so a patient who starts on its product tends to stay. Because the payer is often the buyer, price and reimbursement decisions matter. It listed in London in 2016 after ownership by private-equity firms.
In one line: A UK medtech peer, like a smaller Coloplast.
Moat: narrow (switching costs, brand, distribution). Patients form habits around specific ostomy/wound-care product fits, creating switching costs once established.
Headquarters: London, UK · Founded: 2008 · Employees: 10,910
Size ConvaTec (CTEC.L) is a United Kingdom Health Care company (Medical Specialties) with a market value of $6.78B, the 73rd largest of 355 United Kingdom companies the cockpit tracks. Shares closed at £270.00 on 18 Nov 2026.
Performance Over six months the shares gained 37.1%, against +25.7% for the median peer and +0.1% for the United Kingdom market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 1.9% over the last twelve months (peer median +8.1%); the operating margin is 16.2% (peer median 16.8%).
Valuation It trades at 17.7× forward earnings against a peer median of 20.9× (4th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +13 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.3 points above its cost of capital (9.5% WACC).
Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | £1.86B | £1.85B | £1.79B | £1.72B | £1.68B |
| Revenue growth | — | +3% | +4% | +2% | — |
| Gross profit | £1.02B | £1.01B | £969M | £932M | £868M |
| EBITDA | £469M | £478M | £439M | £403M | £364M |
| Net income | £92.6M | £133M | £149M | £105M | £51.1M |
| Free cash flow | £142M | £254M | £214M | £185M | £148M |
| Capital expenditure | £180M | £140M | £95.6M | £104M | £117M |
| Total debt | n/a | £1.13B | £959M | £1.03B | £1.08B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| ConvaTec CTEC.L | $6.78B | +37% | +2% | 16% | 17.7× | 17.2% |
| Coloplast A/S COLO-B.CO | $16.6B | +24% | +4% | 25% | 20.0× | -2.1% |
| Smith & Nephew SN..L | $12.6B | +1% | +2% | 17% | 14.2× | 11.1% |
| Solventum SOLV | $14.7B | +14% | -3% | 8% | 11.7× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CTEC.L | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +14.7% | +11.2% | 8th highest of 21 |
| 6-month return | +37.1% | +25.7% | 7th highest of 21 |
| Distance from 52-week high | -0.9% | -7.2% | 3rd highest of 21 |
| Revenue growth (TTM) | +1.9% | +8.1% | 6th lowest of 21 |
| Operating margin | 16.2% | 16.8% | 11th highest of 21 |
| Forward P/E | 17.7× | 20.9× | 4th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 17.2% | 9.8% | 3rd most demanding of 19 |
| Growth delivered (Del g) | +4.6% | +9.7% | 4th lowest of 19 |
| Hurdle (Req g minus delivered) | +12.6 pp | +1.4 pp | 4th most demanding of 19 |
| ROIC minus cost of capital | +0.3 pp | +3.5 pp | 4th lowest of 21 |
| EV / EBITDA | 13.6× | 15.4× | 8th cheapest of 18 |
| Net debt / EBITDA | 2.6× | 0.5× | 4th most indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ConvaTec CTEC.L | United Kingdom | $6.78B | +37% | +2% | 16% | 17.7× | 17.2% | +4.6% |
| Ypsomed YPSN.SW | Switzerland | $6.83B | +27% | -13% | 30% | 31.7× | n/a | n/a |
| Cochlear COH.AX | Australia | $6.72B | +58% | -1% | 13% | 29.1× | 23.9% | +9.3% |
| Lantheus LNTH | United States | $6.67B | +6% | +2% | 19% | 15.5× | 0.4% | +35.3% |
| Teleflex TFX | United States | $6.58B | +23% | -29% | 12% | 16.7× | 16.5% | -4.7% |
| Asahi Intecc 7747.T | Japan | $7.09B | +24% | +23% | 32% | 29.7× | 15.1% | +18.8% |
| Bausch + Lomb BLCO.TO | Canada | $7.41B | +35% | +11% | 9% | 18.3× | 12.0% | +10.0% |
| Getinge GETI-B.ST | Sweden | $7.45B | +40% | -4% | 14% | 21.1× | 5.0% | +3.2% |
| Shenzhen New Industries Biomedical Engineering 300832.SZ | China | $7.50B | +21% | +7% | 43% | 26.9× | 2.9% | +15.7% |
| APT Medical 688617.SS | China | $6.06B | +23% | +28% | 37% | 38.6× | 9.0% | +40.1% |
| Sysmex 6869.T | Japan | $8.06B | +58% | +8% | 13% | 32.0× | 4.4% | +10.4% |
| Shimadzu 7701.T | Japan | $8.14B | +24% | +8% | 14% | 21.0× | 8.3% | +7.3% |
| Haemonetics HAE | United States | $5.59B | +106% | +4% | 19% | 20.7× | 10.9% | +8.9% |
| LivaNova LIVN | United States | $5.21B | +28% | +12% | 15% | 20.9× | 14.2% | +8.2% |
| Merit Medical Systems MMSI | United States | $5.15B | +33% | +9% | 14% | 19.1× | 12.6% | +9.5% |
| Globus Medical GMED | United States | $9.34B | -16% | +13% | 23% | 13.7× | 4.6% | +30.1% |
| Intco Medical Technology 300677.SZ | China | $4.82B | -2% | +33% | 20% | 18.5× | -3.5% | -6.4% |
| DiaSorin DIA.MI | Italy | $4.81B | +24% | -3% | 24% | 20.5× | 4.1% | +6.3% |
| MiniMed MMED | United States | $4.78B | +46% | +14% | 14% | 26.3× | n/a | n/a |
| Bruker BRKR | United States | $9.66B | +43% | +2% | 10% | 27.0× | 25.4% | +11.6% |
| Insulet PODD | United States | $9.71B | -11% | +26% | 18% | 18.6× | 10.6% | +24.5% |